Cargando…

Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component

OBJECTIVES: The aim of this study was to evaluate the correlation between clinical histopathologic features and micropapillary (MP) ratio with the maximum standardized uptake value (SUV(max)) derived from (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Akgün, Elife, Alçın, Göksel, Kelten Talu, Esra Canan, Çermik, Tevfik Fikret, Söylemez Akkurt, Tuçe, Şen, Ebru, Arslan, Esra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600551/
https://www.ncbi.nlm.nih.gov/pubmed/37870289
http://dx.doi.org/10.4274/mirt.galenos.2023.06078
_version_ 1785126011653849088
author Akgün, Elife
Alçın, Göksel
Kelten Talu, Esra Canan
Çermik, Tevfik Fikret
Söylemez Akkurt, Tuçe
Şen, Ebru
Arslan, Esra
author_facet Akgün, Elife
Alçın, Göksel
Kelten Talu, Esra Canan
Çermik, Tevfik Fikret
Söylemez Akkurt, Tuçe
Şen, Ebru
Arslan, Esra
author_sort Akgün, Elife
collection PubMed
description OBJECTIVES: The aim of this study was to evaluate the correlation between clinical histopathologic features and micropapillary (MP) ratio with the maximum standardized uptake value (SUV(max)) derived from (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in treatment naïve breast cancer. METHODS: Twenty-nine patients diagnosed with breast cancer with a MP component who underwent PET/CT imaging before any local and/or systemic treatment were included in this retrospective study. All clinical histopathological features were recorded. SUV(max) values were measured from (18)F-FDG PET images for primary tumors and metastatic axillary lymph nodes. RESULTS: MP component percentage did not correlate with any clinical histopathological features except age. At early ages, the MP component ratio was significantly higher. Our results showed that there is no significant correlation between the SUV(max) value and MP component percentage. CONCLUSION: A high SUV(max) value is generally expected in aggressive malignancies. However, this assumption may not be valid for the MP subgroup, which has an aggressive course compared to other subgroups in breast cancer.
format Online
Article
Text
id pubmed-10600551
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-106005512023-10-27 Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component Akgün, Elife Alçın, Göksel Kelten Talu, Esra Canan Çermik, Tevfik Fikret Söylemez Akkurt, Tuçe Şen, Ebru Arslan, Esra Mol Imaging Radionucl Ther Original Article OBJECTIVES: The aim of this study was to evaluate the correlation between clinical histopathologic features and micropapillary (MP) ratio with the maximum standardized uptake value (SUV(max)) derived from (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in treatment naïve breast cancer. METHODS: Twenty-nine patients diagnosed with breast cancer with a MP component who underwent PET/CT imaging before any local and/or systemic treatment were included in this retrospective study. All clinical histopathological features were recorded. SUV(max) values were measured from (18)F-FDG PET images for primary tumors and metastatic axillary lymph nodes. RESULTS: MP component percentage did not correlate with any clinical histopathological features except age. At early ages, the MP component ratio was significantly higher. Our results showed that there is no significant correlation between the SUV(max) value and MP component percentage. CONCLUSION: A high SUV(max) value is generally expected in aggressive malignancies. However, this assumption may not be valid for the MP subgroup, which has an aggressive course compared to other subgroups in breast cancer. Galenos Publishing 2023-10 2023-10-20 /pmc/articles/PMC10600551/ /pubmed/37870289 http://dx.doi.org/10.4274/mirt.galenos.2023.06078 Text en ©Copyright 2023 by the Turkish Society of Nuclear Medicine / Molecular Imaging and Radionuclide Therapy published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Akgün, Elife
Alçın, Göksel
Kelten Talu, Esra Canan
Çermik, Tevfik Fikret
Söylemez Akkurt, Tuçe
Şen, Ebru
Arslan, Esra
Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component
title Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component
title_full Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component
title_fullStr Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component
title_full_unstemmed Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component
title_short Investigation of Clinical Histopathologic Features and Metabolic Parameters of (18)F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component
title_sort investigation of clinical histopathologic features and metabolic parameters of (18)f-fdg pet/ct in invasive breast carcinoma with a micropapillary component
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600551/
https://www.ncbi.nlm.nih.gov/pubmed/37870289
http://dx.doi.org/10.4274/mirt.galenos.2023.06078
work_keys_str_mv AT akgunelife investigationofclinicalhistopathologicfeaturesandmetabolicparametersof18ffdgpetctininvasivebreastcarcinomawithamicropapillarycomponent
AT alcıngoksel investigationofclinicalhistopathologicfeaturesandmetabolicparametersof18ffdgpetctininvasivebreastcarcinomawithamicropapillarycomponent
AT keltentaluesracanan investigationofclinicalhistopathologicfeaturesandmetabolicparametersof18ffdgpetctininvasivebreastcarcinomawithamicropapillarycomponent
AT cermiktevfikfikret investigationofclinicalhistopathologicfeaturesandmetabolicparametersof18ffdgpetctininvasivebreastcarcinomawithamicropapillarycomponent
AT soylemezakkurttuce investigationofclinicalhistopathologicfeaturesandmetabolicparametersof18ffdgpetctininvasivebreastcarcinomawithamicropapillarycomponent
AT senebru investigationofclinicalhistopathologicfeaturesandmetabolicparametersof18ffdgpetctininvasivebreastcarcinomawithamicropapillarycomponent
AT arslanesra investigationofclinicalhistopathologicfeaturesandmetabolicparametersof18ffdgpetctininvasivebreastcarcinomawithamicropapillarycomponent